Scientists have completed the Phase I / II global clinical trial with a new type of cancer drug that can enter tumor cells and attack them from within. This "Trojan Horse" approach was employed in advanced, drug-resistant cancers and showed promising results in a small percentage of them.
The results reported in The Lancet Oncology so that the tumor either shrink or cease to grow in 27 percent of patients with bladder cancer, 26.5 percent of cervical cancer patients, 14 percent of ovarian cancer sufferers, 13 percent of esophageal cancer patients , 13 percent of patients with non-small cell lung cancer and 7 percent of patients with endometrial cancer. Unfortunately, no changes were reported in men with prostate cancer.
The new drug is called Tisotumab Vedotin (TV for short), and the clinical trial was led by a team from the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust. The sample originally recruited 27 patients to assess the safety of the drug and the correct dose and was then opened up to an additional 1
"Our early study shows that it has the potential to treat a large number of different cancers and especially some of those with very poor survival rates," Leading researcher Professor Johann de Bono said in a statement. "TVs have manageable side effects, and we saw some good reactions in the patients in our trials, all of whom had late stage cancer that had been pretreated with other drugs and had run out of other options."  The innovative approach is something that many have been waiting for. In spite of incredible advances over the last few decades, there are several cancers, for which treatments do not always succeed, especially if they have begun to spread. This may be the start of a new arsenal against these types of diseases. The team is already looking at the next steps.
"We have already begun further trials on this new drug in various tumor types and as another treatment for cervical cancer where the response rate was particularly high. We also develop a test to select the most likely patients to respond," they added. Bono.
In 2018, 9.6 million people died of cancer, the second leading cause of death globally. The World Health Organization estimates that up to 50 percent of all cancer cases can be prevented.